Blair William & Co. IL Has $28.88 Million Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Blair William & Co. IL decreased its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 3.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,261,677 shares of the biopharmaceutical company’s stock after selling 89,031 shares during the quarter. Blair William & Co. IL owned approximately 1.72% of Dynavax Technologies worth $28,882,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. PDT Partners LLC bought a new stake in shares of Dynavax Technologies during the third quarter worth about $3,967,000. WINTON GROUP Ltd grew its holdings in Dynavax Technologies by 339.0% during the 4th quarter. WINTON GROUP Ltd now owns 426,814 shares of the biopharmaceutical company’s stock worth $5,450,000 after acquiring an additional 329,579 shares during the last quarter. Nordea Investment Management AB increased its position in Dynavax Technologies by 42.7% in the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock valued at $10,034,000 after acquiring an additional 232,690 shares during the period. Barclays PLC raised its stake in shares of Dynavax Technologies by 137.4% during the third quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company’s stock valued at $3,371,000 after acquiring an additional 175,118 shares during the last quarter. Finally, Bank of Montreal Can lifted its holdings in shares of Dynavax Technologies by 8.3% during the third quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock worth $11,848,000 after purchasing an additional 82,449 shares during the period. Institutional investors own 96.96% of the company’s stock.

Analysts Set New Price Targets

DVAX has been the subject of a number of recent research reports. The Goldman Sachs Group downgraded Dynavax Technologies from a “neutral” rating to a “sell” rating and decreased their price objective for the company from $15.00 to $12.00 in a report on Tuesday, February 11th. StockNews.com raised Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Monday, February 24th. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 21st. Finally, HC Wainwright reissued a “buy” rating and set a $31.00 target price on shares of Dynavax Technologies in a research report on Friday, February 21st.

Dynavax Technologies Stock Up 1.0 %

Shares of Dynavax Technologies stock opened at $13.72 on Friday. The stock’s 50-day moving average is $13.32 and its 200 day moving average is $12.47. Dynavax Technologies Co. has a one year low of $9.74 and a one year high of $14.63. The firm has a market cap of $1.70 billion, a price-to-earnings ratio of 76.22 and a beta of 1.23. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, hitting the consensus estimate of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The company had revenue of $72.03 million during the quarter, compared to the consensus estimate of $72.70 million. Equities research analysts anticipate that Dynavax Technologies Co. will post 0.32 EPS for the current year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.